Capstone Capital Management Ltd Purchases Shares of 100,324 Direxion Daily S&P Biotech Bear 3x Shares $LABD

Capstone Capital Management Ltd purchased a new position in shares of Direxion Daily S&P Biotech Bear 3x Shares (NYSEARCA:LABD) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 100,324 shares of the company’s stock, valued at approximately $1,635,000. Direxion Daily S&P Biotech Bear 3x Shares comprises about 1.6% of Capstone Capital Management Ltd’s portfolio, making the stock its 17th biggest position. Capstone Capital Management Ltd owned about 1.63% of Direxion Daily S&P Biotech Bear 3x Shares at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in shares of Direxion Daily S&P Biotech Bear 3x Shares during the 3rd quarter worth about $5,063,000. Jump Financial LLC purchased a new position in Direxion Daily S&P Biotech Bear 3x Shares in the fourth quarter valued at approximately $2,966,000. Qube Research & Technologies Ltd purchased a new position in Direxion Daily S&P Biotech Bear 3x Shares in the third quarter valued at approximately $983,000. Boothbay Fund Management LLC purchased a new position in Direxion Daily S&P Biotech Bear 3x Shares in the third quarter valued at approximately $893,000. Finally, Group One Trading LLC acquired a new position in Direxion Daily S&P Biotech Bear 3x Shares during the second quarter valued at approximately $337,000.

Direxion Daily S&P Biotech Bear 3x Shares Trading Up 1.4%

LABD opened at $7.02 on Thursday. Direxion Daily S&P Biotech Bear 3x Shares has a 52-week low of $6.84 and a 52-week high of $69.69. The company has a 50 day moving average of $12.34 and a two-hundred day moving average of $16.10.

About Direxion Daily S&P Biotech Bear 3x Shares

The Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.